Comparing Surgery Plus Anti-VEGF Injections to Anti-VEGF Alone for Submacular Haemorrhage in Wet Age-Related Macular Degeneration
Led by King's College Hospital NHS Trust · Updated on 2026-09-11
210
Participants Needed
42
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
The trial investigates treatments for submacular haemorrhage SMH, a serious complication of wet age-related macular degeneration AMD that can cause severe vision loss. Researchers aim to compare the current standard treatment of anti-VEGF injections with a combination of anti-VEGF injections plus eye surgery to see if surgery improves vision outcomes. This is a phase 3 randomized controlled trial involving adults aged 50 and older with SMH due to wet AMD.
Participants are randomly assigned to one of two groups one group receives standard anti-VEGF injections starting at baseline and continuing monthly for three doses, then every two months until 12 months. The other group receives the same anti-VEGF injection schedule combined with vitrectomy surgery, which involves removing the eyes vitreous gel, injecting a clot-busting drug TPA, and filling the eye with gas to help clear the blood clot. Surgery patients also follow specific head positioning after the procedure and have follow-up visits the day after and one week after surgery.
Throughout the 12-month study, participants attend regular visits for injections and vision assessments, including tests of visual acuity and questionnaires about visual function and quality of life. Researchers measure vision improvement using Early Treatment of Diabetic Retinopathy Study ETDRS letter scores and other vision-related tests. Safety and vision are monitored with clinical exams at 6 and 12 months, and adherence to treatment schedules is tracked to evaluate the effectiveness of the treatments.
CONDITIONS
Brief Title
Vitrectomy, Subretinal Tissue Plasminogen Activator (TPA) and Intravitreal Gas for Submacular Haemorrhage Secondary to Exudative (Wet) Age-related Macular Degeneration (TIGER).
Research Team
R
Riti Desai, M.Sc.,M.Phil.
L
Lisa Ramazzotto, M.Pharm
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match. Sign up to get personalized trial recommendations delivered to your inbox.
Submacular haemorrhage (SMH) caused by treatment-naïve or previously treated wet age-related macular degeneration, including types like CNV, IPCV, and RAP
SMH involving the center of the retina (foveal centre) measuring at least 1 disc diameter
Sub-neuroretinal haemorrhage at least 125 microns thick at the foveal centre measured by OCT
Best corrected visual acuity (BCVA) between counting fingers and 70 ETDRS letters in the study eye
You will not qualify if you...
Serious allergy to fluorescein or indocyanine green (ICG)
Hypersensitivity to alteplase, gentamicin, arginine, phosphoric acid, polysorbate 80, or aflibercept
Stroke, transient ischemic attack, or heart attack within the last 6 months
Participation in another interventional study within 12 weeks or planned during this study
Women who are pregnant, breastfeeding, or planning pregnancy during the trial; and requirements for effective birth control for sexually active women and men
INR greater than 3.5 unless safely managed before surgery
Unwilling or unable to return for all scheduled follow-ups
Any condition preventing informed consent or protocol compliance, such as dementia or serious illness
SMH present for more than 15 days
SMH caused by eye diseases other than wet AMD
Active proliferative diabetic retinopathy
Current intraocular inflammation or infection (except blepharitis)
High myopia greater than 6 diopters
Aphakia (absence of the lens)
Ocular conditions preventing vision improvement after SMH resolution
Poor pupil dilation or media opacities preventing eye examination or imaging
Eye surgery within 12 weeks except uncomplicated cataract surgery within 8 weeks
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 baseline visit
Treatment
Duration - 12 months
Participants receive either anti-VEGF injections alone or anti-VEGF injections combined with eye surgery including vitrectomy, subretinal TPA injection, and gas tamponade.
Monthly injections for 3 months, then every 2 months; surgery group has additional post-operative visits at day 1 and week 1
Follow-up
Duration - Up to 12 months
Participants have vision assessments and clinical examinations at 6 and 12 months to monitor treatment effects and safety.
2 visits (6 and 12 months)
How is the study designed?
Study Type
INTERVENTIONAL
Masking
SINGLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Similar Trials
Adaptive Optics Imaging to Study Retinal Diseases and Healthy Eyes for Improved Diagnosis and Management
Pilot Study Testing a New Auto-aligned Handheld OCT Device for Imaging the Retina in Adults and Children
Comparing Autologous Serum Tears With and Without Sodium Hyaluronate for Treating Moderate-to-Severe Dry Eye Disease in Adults
AI System Development to Identify Neuro-Ophthalmological Conditions from Eye Photos in Emergency Departments
Study of Insulin Eye Drops to Help Healing After Corneal Crosslinking Surgery in Patients With Keratoconus
Randomized, Double-Masked, Placebo-Controlled Study Evaluating Safety and Pharmacology of ETHY-001 in Thyroid Eye Disease
Extension Study of Two Oral Linsitinib Doses in Adults With Active, Moderate to Severe Thyroid Eye Disease
Studying TRYPTYR to Improve Quality of Life and Work Ability in Adults with Dry Eye Disease
IRIS Registry National Clinical Registry for Eye Disease Care and Quality Improvement
Michigan SIGHT 2 Study Comparing Technology-Enhanced Eye Disease Detection to Standard Exams for Glaucoma, Cataracts, and Diabetic Retinopathy
Have more questions? Get in touch with our team for quick support
Published Research Related To This Trial
Vitrectomy, subretinal Tissue plasminogen activator and Intravitreal Gas for submacular haemorrhage secondary to Exudative Age-Related macular degeneration (TIGER): update to study protocol and addition of a statistical analysis plan and health economic analysis plan for a randomised controlled surgical trial.
Vitrectomy, subretinal Tissue plasminogen activator and Intravitreal Gas for submacular haemorrhage secondary to Exudative Age-Related macular degeneration (TIGER): study protocol for a phase 3, pan-European, two-group, non-commercial, active-control, observer-masked, superiority, randomised controlled surgical trial.